Reaction
Therapeutic Response Delayed reporting signals
As of the last recalculation, Therapeutic Response Delayed appears in 2,753 FAERS reports alongside 38 co-occurring drug terms. The strongest observed disproportionality signal is EPTINEZUMAB-JJMR (PRR 104.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Eptinezumab-Jjmr | 120 | 104.2 | 105.6 |
| Dutasteride | 30 | 28.2 | 28.3 |
| Daptomycin | 30 | 24.8 | 24.9 |
| Rimegepant Sulfate | 21 | 12.6 | 12.6 |
| Loperamide Hydrochloride And Dimethicone | 49 | 11.7 | 11.8 |
| Sumatriptan | 52 | 10.5 | 10.5 |
| Blinatumomab | 14 | 10.2 | 10.2 |
| Erythropoietin | 27 | 10.0 | 10.0 |
| Suvorexant | 14 | 8.2 | 8.2 |
| Romiplostim | 16 | 8.1 | 8.1 |
| Insulin Human | 35 | 6.7 | 6.7 |
| Levocetirizine Dihydrochloride | 19 | 6.0 | 6.0 |
| Linaclotide | 21 | 6.0 | 6.0 |
| Insulin Glulisine | 8 | 6.0 | 6.0 |
| Loperamide Hydrochloride | 34 | 5.8 | 5.8 |
| Tramadol Hydrochloride | 27 | 5.5 | 5.5 |
| Galcanezumab-Gnlm | 22 | 5.3 | 5.3 |
| Sumatriptan Succinate | 17 | 5.1 | 5.1 |
| Levodopa | 8 | 5.0 | 5.0 |
| Linezolid | 19 | 4.9 | 4.9 |
| Nilotinib | 18 | 4.6 | 4.6 |
| Insulin Lispro | 81 | 4.5 | 4.5 |
| Triamcinolone Acetonide | 17 | 4.2 | 4.2 |
| Etanercept | 300 | 4.1 | 4.1 |
| Tadalafil | 53 | 4.1 | 4.1 |
| Onabotulinumtoxina | 40 | 4.0 | 4.0 |
| Vibegron | 4 | 3.8 | 3.8 |
| Esketamine Hydrochloride | 8 | 3.4 | 3.4 |
| Buprenorphine | 38 | 3.1 | 3.1 |
| Peginterferon Alfa-2A | 22 | 3.1 | 3.1 |
| Dasatinib | 14 | 2.9 | 2.9 |
| Acetaminophen, Aspirin (Nsaid) And Caffeine | 6 | 2.7 | 2.7 |
| Eltrombopag Olamine | 8 | 2.6 | 2.6 |
| Secukinumab | 55 | 2.6 | 2.6 |
| Erenumab-Aooe | 16 | 2.2 | 2.2 |
| Droxidopa | 5 | 1.8 | 1.8 |
| Dupilumab | 100 | 1.6 | 1.6 |
| Guselkumab | 6 | 1.3 | 1.3 |